Compare DGICB & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DGICB | ESPR |
|---|---|---|
| Founded | 1986 | 2008 |
| Country | United States | United States |
| Employees | 851 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 654.6M | 731.9M |
| IPO Year | N/A | 2013 |
| Metric | DGICB | ESPR |
|---|---|---|
| Price | $19.13 | $3.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.75 |
| AVG Volume (30 Days) | 416.0 | ★ 17.2M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | N/A | ★ 60.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $403,135,000.00 |
| Revenue This Year | $2.26 | N/A |
| Revenue Next Year | N/A | $12.81 |
| P/E Ratio | $8.06 | ★ N/A |
| Revenue Growth | N/A | ★ 21.31 |
| 52 Week Low | $13.84 | $0.76 |
| 52 Week High | $20.30 | $4.18 |
| Indicator | DGICB | ESPR |
|---|---|---|
| Relative Strength Index (RSI) | 54.00 | 70.78 |
| Support Level | $15.57 | $2.37 |
| Resistance Level | $19.72 | $3.15 |
| Average True Range (ATR) | 0.42 | 0.03 |
| MACD | -0.10 | 0.04 |
| Stochastic Oscillator | 75.11 | 96.12 |
Donegal Group Inc is an insurance holding company whose insurance subsidiaries and affiliates offer property and casualty insurance in 21 Mid-Atlantic, Midwestern, Southern, and Southwestern states. It includes three segments: Investments Function, Commercial Lines of Insurance, and Personal Lines of Insurance. The majority of revenue is from the commercial Lines segment. The commercial Lines segment consists mainly of commercial automobile, commercial multi-peril, and workers' compensation policies.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.